New options for drug treatment of obesity in patients with Type 2 diabetes

Diabetic Medicine

Volumn 22, Issue SUPPL. 4, 2005, Pages 23-26

  Kennedy, R L ^a   Khoo, E Y H ^b  

^a JAMES COOK UNIVERSITY   (Australia)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMFEPRAMONE; ANTICONVULSIVE AGENT; EXENDIN 4; GLICLAZIDE; HEMOGLOBIN A1C; LIRAGLUTIDE; LISINOPRIL; METFORMIN; PHENTERMINE; PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; ZONISAMIDE;

ANXIETY DISORDER; BODY MASS; CARDIOMYOPATHY; CLINICAL TRIAL; DIABETIC DIET; DIABETIC HYPERTENSION; DIABETIC OBESITY; DIZZINESS; DRUG CONTRAINDICATION; FEEDING BEHAVIOR; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; LOW CALORY DIET; MEMORY DISORDER; META ANALYSIS; METABOLIC REGULATION; MOOD DISORDER; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; VOMITING;

ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; CANNABINOIDS; CYCLOBUTANES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; LACTONES; MALE; MIDDLE AGED; OBESITY; PIPERIDINES; PYRAZOLES;

EID: 24044495227     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.1761h.x     Document Type: Review

References (20)

1. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532-546.
2. Torgerson Jarl S, Hauptman J, Boldrin Mark N, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-161.
3. Kelley David E, Kuller Lewis H, McKolanis Therese M, Harper P, Mancino J, Kalhan S. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 2004; 27: 33-40.
4. Arterburn David E, Crane Paul K, Veenstra David L. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004; 164: 994-1003.
5. Kim Su H, Lee Young M, Jee Sun H, Nam Chung M. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 2003; 11: 1116-1123.
6. Vettor R, Serra R, Fabris R, Pagano C, Federspil G. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care 2005; 28: 942-949.
7. McNulty Steven J, Ur E, Williams G. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003; 26: 125-131.
8. Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005; 21: 457-468.
9. Cota D, Marsicano G, Tschöp M, Grübler Y, Flachskamm C, Schubert M et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-431.
10. Bensaid M, Gary Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrié P. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908-914.
11. Liu YL, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes Relat Metab Disord 2005; 29: 183-187.
12. Osei Hyiaman D, Depetrillo M, Pacher P, Liu J, Rodaeva S, Bátkai S, et al. Endocannabinoid activation at hepatic CB(1) receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298-1305.
13. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrié P. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet- induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284: R345-R353.
14. Van Gaal Luc F, Rissanen Aila M, Scheen André J, Ziegler O, Rössner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397.
15. Klein Thomas W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005; 5: 400-411.
16. Greeno CG, Wing RR. A double-blind, placebo-controlled trial of the effect of fluoxetine on dietary intake in overweight women with and without binge-eating disorder. Am J Clin Nutr 1996; 64: 267-273.
17. Jain AK, Kaplan RA, Gadde KM, Wadden TA, Allison DB, Brewer ER et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002; 10: 1049-1056.
18. Wilkes Jason J, Nelson E, Osborne M, Demarest Keith T, Olefsky Jerrold M. Topiramate is an insulin-sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats. Am J Physiol Endocrinol Metab 2005; 288: E617-E624.
19. Ortmann S, Kampe J, Gossel M, Bickel M, Geisen K, Jähne G et al. The novel antiobesic HMR1426 reduces food intake without affecting energy expenditure in rats. Obes Res 2004; 12: 1290-1297.
20. Ahrén B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004; 36: 11-12.